“At Xanodyne, I had the distinct pleasure to work, watch and learn from a true leader in the Pharmaceutical Industry, Charmaine Lykins. The marketing efforts that she put fourth towards the launch of Zipsor had a tremendous impact on it's initial success. I hope to one day work with Charmaine on future projects and I aspire to follow a similar path so I can hope to achieve as much as she has in her career. Sandy Franco Xanodyne Pharmaceuticals cell#631-680-2886”
Activity
-
MapLight Therapeutics, Inc. is pioneering the discovery, development and delivery of transformative treatments for brain disorders. Proud to be your…
MapLight Therapeutics, Inc. is pioneering the discovery, development and delivery of transformative treatments for brain disorders. Proud to be your…
Liked by Charmaine Lykins
-
I am excited to join the Board of Directors at Kyverna and work with Warner Biddle, Christi Shaw, and the rest of the team. Kyverna is pioneering…
I am excited to join the Board of Directors at Kyverna and work with Warner Biddle, Christi Shaw, and the rest of the team. Kyverna is pioneering…
Liked by Charmaine Lykins
-
I want to voice the enthusiasm that Dr. Marlene Freeman and I share over the launch of our two new educational programs for early 2026 : The…
I want to voice the enthusiasm that Dr. Marlene Freeman and I share over the launch of our two new educational programs for early 2026 : The…
Liked by Charmaine Lykins
Experience & Education
Licenses & Certifications
Recommendations received
3 people have recommended Charmaine
Join now to viewMore activity by Charmaine
-
Rapid, consistent, and sustained benefits with COMP360 for patients experiencing treatment-resistant depression!! I am proud to have been part of…
Rapid, consistent, and sustained benefits with COMP360 for patients experiencing treatment-resistant depression!! I am proud to have been part of…
Liked by Charmaine Lykins
-
Final #COMP360 Read-Out “The #mushroom does not give you what you want — it gives you what you need.” When we started Compass Pathways in 2017, the…
Final #COMP360 Read-Out “The #mushroom does not give you what you want — it gives you what you need.” When we started Compass Pathways in 2017, the…
Liked by Charmaine Lykins
-
High placebo responses are a huge problem for neuropsychiatry studies. Our team analyzed generalized anxiety disorder trials and found that (as…
High placebo responses are a huge problem for neuropsychiatry studies. Our team analyzed generalized anxiety disorder trials and found that (as…
Liked by Charmaine Lykins
-
Founder and CEO Anirudh Kumar of CarMa Institute shares how conversations at the World Governments Summit (WGS) 2026 in Dubai revealed patient…
Founder and CEO Anirudh Kumar of CarMa Institute shares how conversations at the World Governments Summit (WGS) 2026 in Dubai revealed patient…
Liked by Charmaine Lykins
-
Our Co‑founder and Board Chair, Dr. Steven Paul, recently joined Selina Koch, PhD, on The BioCentury Inc. Show podcast for a wide‑ranging…
Our Co‑founder and Board Chair, Dr. Steven Paul, recently joined Selina Koch, PhD, on The BioCentury Inc. Show podcast for a wide‑ranging…
Liked by Charmaine Lykins
-
Humor in Daily Life: “Coffee! I need coffee!” This thought enters my mind the moment I wake up in an unfamiliar hotel. I go downstairs, hair…
Humor in Daily Life: “Coffee! I need coffee!” This thought enters my mind the moment I wake up in an unfamiliar hotel. I go downstairs, hair…
Liked by Charmaine Lykins
-
𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲: 𝗘𝘃𝗲𝗰𝘅𝗶𝗮 𝗱𝗼𝘀𝗲𝗱 𝗳𝗶𝗿𝘀𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝟭𝗯 𝗧𝗮𝗿𝗴𝗲𝘁 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗦𝘁𝘂𝗱𝘆 Study…
𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲: 𝗘𝘃𝗲𝗰𝘅𝗶𝗮 𝗱𝗼𝘀𝗲𝗱 𝗳𝗶𝗿𝘀𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝟭𝗯 𝗧𝗮𝗿𝗴𝗲𝘁 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗦𝘁𝘂𝗱𝘆 Study…
Liked by Charmaine Lykins
-
Greetings from Rome with my colleagues from BMS Japan. We gathered with GMs and market access experts from around the world to discuss the rapidly…
Greetings from Rome with my colleagues from BMS Japan. We gathered with GMs and market access experts from around the world to discuss the rapidly…
Liked by Charmaine Lykins
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content